SCHEMBL202948

SCHEMBL202948

NS(=O)(=O)c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 17/20 0.81
CA9 Q16790 13/20 0.81
CA12 O43570 12/20 0.81
CA1 P00915 14/20 0.77
CA5A P35218 8/20 0.77
CA7 P43166 8/20 0.77
CA5B Q9Y2D0 8/20 0.77
CA6 P23280 6/20 0.77
CA4 P22748 6/20 0.77
CA14 Q9ULX7 6/20 0.77
CA13 Q8N1Q1 3/20 0.77
USP2 O75604 1/20 0.77
TSHR P16473 1/20 0.77
TDP1 Q9NUW8 1/20 0.77
AGO2 Q9UKV8 1/20 0.77
CA3 P07451 3/20 0.72
PLA2G7 Q13093 1/20 0.71
ALDH1A1 P00352 1/20 0.68
HTT P42858 1/20 0.68
MAPT P10636 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10493509 0.90 CA2 (0.68) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL2798899 0.87 CA2 (1.00) CA2CA9CA12CA1CA5A
SCHEMBL1805283 0.87 CA2 (0.65) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL31544839 0.87 CA2 (1.00) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL740 0.87 CA2 (1.00) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL30659052 0.87 CA2 (1.00) CA2CA9CA12CA1CA5A
SCHEMBL428943 0.85 CA2 (0.62) CA2CA9CA12CA1CA5A
P-Toluenesulfonamide SCHEMBL1331323 0.85 CA2 (1.00) CA2CA9CA12CA1CA5A
SCHEMBL283769 0.85 CA2 (1.00) CA2CA9CA12CA1CA5A
Sulfanilamide SCHEMBL22501553 0.85 CA2 (0.94) CA2CA9CA12CA1CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023285787-A1 SULFUR COMPOUNDS AND PROCESSES AND INTERMEDIATES USEFUL IN THE PREPARATION THEREOF OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2023-01-19 WO claimed
EP-2364300-B1 DIMERIC 1-ARYLPYRAZOLE DERIVATIVES MERIAL INC (US) 2016-10-19 EP claimed
WO-2016087879-A1 FORMATION OF BONDS BY OUTER-SPHERE OXIDATIVE ELECTROPHILIC FLUORINATION UNIVERSITY OF YORK (GB) 2016-06-09 WO claimed
EP-2035390-B1 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof MERIAL INC (US) 2015-12-09 EP claimed
US-8785372-B2 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof AVENTIS AGRICULTURE 2014-07-22 US claimed
US-8642636-B2 Dimeric 1-arylpyrazole derivatives for use against ectoparasites, agricultural pests, and household pests MERIAL LIMITED (US) 2014-02-04 US claimed
US-20130324457-A1 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF AVENTIS AGRICULTURE (FR) 2013-12-05 US claimed
EP-2465851-A1 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof Aventis Agriculture (FR) 2012-06-20 EP claimed
US-20110245157-A1 DIMERIC 1-ARYLPYRAZOLE DERIVATIVES MERIAL, INC. 2011-10-06 US claimed
EP-2364300-A2 DIMERIC 1-ARYLPYRAZOLE DERIVATIVES Merial Ltd. (US) 2011-09-14 EP claimed
US-7759381-B2 1-aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof AVENTIS AGRICULTURE (FR) 2010-07-20 US claimed
WO-2010059719-A2 DIMERIC 1-ARYLPYRAZOLE DERIVATIVES MERIAL LIMITED (US) 2010-05-27 WO claimed
EP-2035390-A2 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF Aventis Agriculture (FR) 2009-03-18 EP claimed
US-20080031902-A1 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof MERIAL, INC. 2008-02-07 US claimed
WO-2008005489-A2 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF AVENTIS AGRICULTURE (FR) 2008-01-10 WO claimed
WO-1995020585-A1 DIASTEREOSELECTIVE PROCESS LEADING TO A KEY INTERMEDIATE FOR THE PREPARATION OF FLUORINATED REVERSE TRANSCRIPTASE INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1995-08-03 WO claimed
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF TRIANA BIOMEDICINES INC (US) 2024-06-13 US disclosed
US-20240108629-A1 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL LIVERPOOL SCHOOL TROPICAL MEDICINE (GB) 2024-04-04 US disclosed
US-3932640-A CEREBRAL VASODILATORS PFIZER INC. (US) 1976-01-13 US disclosed
US-3867391-A Cyclic n-substituted derivatives of 1,4-benzene disulphonamide PFIZER 1975-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080031902-A1 1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof CBR3, CBR1, NR5A2 CA2 1930/4885CA9 966/4885CA12 2234/4885
US-20240190821-A1 SULFONAMIDE SUBSTITUTED N-(1H-INDOL-7-YL)BENZENESULFONAMIDES AND USES THEREOF PACSIN2, TPX2, PRSS12 CA2 3857/4885CA9 4702/4885CA12 4096/4885
US-20110245157-A1 DIMERIC 1-ARYLPYRAZOLE DERIVATIVES AADAC, TYR, AADAT CA2 2227/4885CA9 4501/4885CA12 4688/4885
US-20240108629-A1 AZAQUINAZOLINE DERIVATIVES FOR USE IN TREATING OR PREVENTING DIROFILARIA INFECTION IN A MAMMAL AQP3, AQP1, AQP4 CA2 2137/4885CA9 1945/4885CA12 3686/4885
US-20130324457-A1 1-ARYL-5-ALKYL PYRAZOLE DERIVATIVE COMPOUNDS, PROCESSES OF MAKING AND METHODS OF USING THEREOF CBR3, CBR1, NR5A2 CA2 1940/4885CA9 954/4885CA12 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.